<DOC>
	<DOCNO>NCT01952145</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial compare efficacy safety insulin degludec/liraglutide versus insulin glargine subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Trial Comparing Efficacy Safety Insulin Degludec/Liraglutide Versus Insulin Glargine Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes mellitus HbA1c 7.010.0 % [ 5386 mmol/mol ] ( inclusive ) central laboratory analysis Current treatment insulin glargine least 90 day prior screen Stable daily dose insulin glargine 20 unit 50 unit ( inclusive ) least 56 day prior screen . Total daily dose within range 2050 unit , inclusive , day screening , individual fluctuation plus/minus 10 procent within 56 day prior screen acceptable Stable daily dose metformin ( equal 1500 mg max tolerate dose ) least 90 day prior screen Body mass index ( BMI ) equal 40 kg/m^2 Any use oral antidiabetic agent ( OADs ) ( except metformin ) within 90 day prior Visit 1 ( screen ) Current use drug ( except metformin insulin glargine ) anticipate change inconcomitant medication , investigator 's opinion could interfere glucose metabolism ( e.g . systemic corticosteroid ) Previous and/or current treatment insulin regimen basal insulin , e.g . prandial premixed insulin ( short term treatment due intercurrent illness includinggestational diabetes allow discretion investigator ) Previous and/or current treatment glucagonlike peptide1 ( GLP1 ) receptor agonist ( e.g . exenatide , liraglutide ) Impaired liver function , define ALAT ( alanine aminotransferase ) equal 2.5 time upper normal range ( UNR ) Impaired renal function define serumcreatinine equal 133 micromol/L ( equal 1.5 mg/dL ) males equal 125 micromol/L ( 1.4 mg/dL ) female , allow accord local contraindication metformin Screening calcitonin equal 50 ng/L Personal family history medullary thyroid carcinoma ( MTC ) multiple endocrine neoplasia type 2 ( MEN2 ) History chronic pancreatitis idiopathic acute pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>